Anita Brikman: There Are Countless More Individuals Who Would Benefit from Access to Plasma-Derived Medicines
AnitaĀ Brikman, President and CEO of the Plasma Protein Therapeutics Association (PPTA), shared onĀ LinkedIn:
āAs International Plasma Awareness Week comes to a close, Iām grateful to all who supported the incredible efforts to recognize the lifesaving power of plasma and plasma donors. It was truly moving to see how Plasma Powers Possibility for so many around the globe.
But it is also clear that our mission doesnāt stop here. There are countless more individuals who would benefit from access to plasma-derived medicines, especially those in lower and middle income countries where the availability of treatment for rare diseases is limited at best.
The Plasma Protein Therapeutics Association (PPTA) efforts around awareness, advocacy, and access will continue on a daily basis. Because in reality, every week should be an awareness week filled with opportunities to reach out and educate. Pictured below are some of our awareness and activities from IPAW2025 including a powerful patient webinar, a Brussels panel on the Critical Medicines Act, a moving patient and donor meeting with GBS|CIDP Foundation International, and just one of the many patient testimonials we received over the last few days.
Next week, the momentum continues at the Plasma Protein Forum, where industry leaders, health care providers, and patient advocates will come together to advance innovation and address timely issues that impact the entire plasma community.
Thereās still time to register, and I hope to see many of you there.
Visit the forum for more details on next weekās gathering.ā

Stay updated withĀ Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leaderās Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbachās Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
